Created in 2015
ViroVet pioneers in developing novel and innovative vaccines based on a unique proprietary technology platform originating from the Rega Institute for Medical Research of KU Leuven. With this technology platform, vaccines can be designed and produced faster and more cost-effectively. The vaccines are tailor-made and are thermostable thereby removing any cold-chain requirement. The company also develops fast-acting antiviral drugs that are critical to the effective control and treatment of respiratory diseases of cattle and swine, thereby reducing secondary bacterial infections and the associated use of antibiotics. Following successful trials, the company has now entered full development of its BVD antiviral drug.